What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody”In the company’s words, NCT06621251 on ClinicalTrials.gov
- Tested for
- Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee
- Main trialPhase 2
- “TRL1068 is expected to eliminate the pathogen-protecting biofilm in the prosthetic joint and surrounding tissue, thus making pathogens substantially more susceptible to established antibiotic treatment regimens. This Phase 2 study is designed to assess efficacy and safety of TRL1068 in combination with a DAIR (debridement, antibiotics, and implant retention) procedure for chronic prosthetic joint infections of the knee and hip, specifically, eliminating the need for the standard of care 2-stage exchange surgery, so that the original prosthesis can be retained.”In the company’s words, NCT06621251 on ClinicalTrials.gov
Coming up2
- DecPhase 1 trial completes · ClinicalTrials.gov
- Apr 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | Apr 2027 | Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint Infection | |
| Phase 1Not yet recruiting | Dec 2026 | Study to Evaluate Safety and Activity of Inhaled TRL1068 in Healthy Volunteers | |
| Phase 1Completed | 13 Mar 2024 | Study to Evaluate Safety and Activity of TRL1068 in Prosthetic Joint Infections | |
| Phase 1Unknown | Jan 2025 | Study to Evaluate Safety and Activity of TRL1068 in Chronic Rhinosinusitis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026